Interplay between inflammation and degeneration: Using inclusion body myositis to study "neuroinflammation"

Annals of Neurology

Volumn 64, Issue 1, 2008, Pages 1-3

  Dalakas, Marinos C ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HUMAN; IMMUNOPATHOGENESIS; INCLUSION BODY MYOSITIS; INFLAMMATION; NERVE DEGENERATION; NEUROPATHOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ENCEPHALITIS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION MEDIATORS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY; NERVE DEGENERATION; NEURODEGENERATIVE DISEASES;

EID: 48949099563     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21452     Document Type: Editorial

References (19)

1. Dalakas MC. Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006;2:437-447.
2. Askanas V, Engel WK. Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol 2003;15:737-744.
3. Mikol J, Engel AG. Inclusion body myositis. In Engel AG, Franzini-Armstrong C, eds. Myology. 2nd ed. New York: McGraw-Hill, 2004:1367-1388.
4. LunemannJD, Schmidt J, Dalakas MC, Munz C. beta-Amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007;61:476-483.
5. Kitazawa. Ann Neurol 2008;63.
6. Schmidt J, Barthel K, Wrede A, et al. Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle. Brain 2008;131:1228-1240.
7. Dalakas MC. Inflammatory, immune and viral aspects of inclusion-body myositis. Neurology 2006;66(suppl):S33-S38.
8. Dalakas MC, Rakocevic G, Shatunov A, et al. IBM with HIV infection: 4 new cases with clonal expansion of viral-specific T cells. Ann Neurol 2007;61:466-475.
9. Pruitt JN 2nd, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996;39:139-143.
10. Salajegheh M, Rakocevic G, Raju R, et al. T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology 2007;69:1672-1679.
11. Nagaraju K, Casciola-Rosen L, Lundberg I, et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum 2005;52:1824-1835.
12. Selcen D, Ohno K, Engel AG. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 2004; 127:439-451.
13. Ferrer I, Carmona M, Blanco R, et al. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis. Brain Pathol 2005;15: 101-108.
14. Spuler S, Carl M, Zabojszcza J, Straub V, et al. Dysferlin-deficient muscular dystrophy features amyloidosis. Ann Neurol 2008;63:323-328.
15. Semino-Mora C, Dalakas MC. Rimmed vacuoles with β-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Human Pathol 1988;29:1128-1133.
16. Dalakas MC, Engel WK. Amyloid in hereditary amyloid polyneuropathy is related to prealbumin. Arch Neurol 1981;38: 420-422.
17. Dalakas MC, Rakocevic G, McElroy B, et al. Alemtuzumab (CAMPATH 1-H) therapy in sporadic Inclusion Body Myositis (sIBM) alters disease progression and suppresses endomysial inflammation. Ann Neurol 2007;62:560-565.
18. Relkin N, Tsakanikas DI, Adamiak B, et al. A double blind, placebo controlled, phase II clinical trial of IVIg for treatment of Alzheimer's disease. Neurology 2008;(suppl 1):A393.
19. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDS and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invert 2003;112:440-449.